For example, in MS patients, NAT therapy leads to the reduction of IL-1 and IL-8 in the CSF and a reduction of TNFα, IL-6 and a range of other proinflammatory molecules in serum [135, 136]. This evidence concerns the gene IL6 and myeloid sarcoma.